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Background: Poly (ethylene glycol) (PEG) has attracted broad interest for tissue
engineering applications. The aim of this study was to synthesize 4-arm -PEG-20kDa
with the terminal group of diacrylate (4-arm-PEG-DA) and evaluate its dual
functionality for decellularized porcine aortic valve (DAV) based on its mechanical
and biological properties.
Methods: 4-arm-PEG-DA was synthesized by graft copolymerization of linear PEG
20,000 monomers, and characterized by IR1H NMR and 13C NMR; PEGylation of DAV
was achieved by the Michael addition reaction between propylene acyl and thiol, its
effect was tested by uniaxial planar tensile testing, hematoxylin and eosin (HE) and
scanning electron microscopy (SEM). Gly-Arg-Gly-Asp-Ser-Pro-Cys (GRGDSPC)
peptides and vascular endothelial growth factor-165 (VEGF165) were conjugated onto
DAV by branched PEG-DA (GRGDSPC-PEG-DAV-PEG-VEGF165).
Results: Mechanical testing confirmed that PEG-cross-linking significantly enhanced
the tensile strength of DAV. Immunofluoresce confirmed the GRGDSPC peptides
and VEGF165 were conjugated effectively onto DAV; the quantification of
conjunction was completed roughly using spectrophotometry and ELISA. The
human umbilical vein endothelial cells (HUVECs) grew and spread well on the
GRGDSPC-PEG-DAV-PEG-VEGF165.
Conclusions: Therefore, PEGylation of DAV not only can improve the tensile strength
of DAV, and can also mediate the conjugation of bioactive molecule (VEGF165 and
GRGDSPC peptides) on DAV, which might be suitable for further development of
tissue engineered heart valve.
Keywords: Decellularized valves, Polyethylene glycol, GRGDSPC peptides, VEGF165,
Michael addition reactionIntroduction
Heart valve disease is considered to be among the many factors that are significant for
mortality throughout the world. Prosthetic valve implantation utilizing a mechanical
prosthetic valve or bioprosthetic heart valve is the most common treatment for valvu-
lar heart disease. However, both these approaches have shortcomings. These shortcom-
ings including the risk of: embolism, wear and an inability to grow, which makes them
unsuitable for treating congenital heart defects. Consequently, many researchers are
now exploring tissue engineering strategies to develop heart valves equivalent [1,2].© 2013 Zhou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Two categories of materials are used as the scaffold to construct TEHV, namely poly-
mer scaffolds and decellularized allogenic or xenogenic scaffolds [3]. Polymer scaffolds
can be derived from biological or synthetic source. Biological polymers possess intrinsic
cell compatibility as most are structural components familiar to cells, but also tend to
be mechanically weak and difficult to manipulate. Synthetic sources are easily tailored
and can be reproduced readily, allowing for novel structural designs that can control
mechanical properties, surface topography, and porosity with limitations including un-
certainties regarding the degradation rate and products as well as cell compatibility
[4,5]. Decellularized allogenic and xenogenic scaffolds have natural three-dimensional
(3-D) structures and extracellular matrix (ECM) composition. However, because the ap-
plication of human decellularized allografts is limited due to worldwide organ scarcity,
decellularized xenogeneic tissues become highly attractive scaffold materials for tissue
engineering (TE) [6]. Among heterogeneous decellularized valves, especially decellularized
porcine aortic valves have been used for the preparation of tissue engineered heart valves
(TEHV) [7-9], due to their similarity with human heart valves in 3-D structures, ECM
composition, and rich source [6,10,11]. However, studies found that decellularization may
lead to part of the collagen fibers may breaking and a reduction of collagen cross-linking,
which in turn may decrease the mechanical strength including ultimate tensile strengths
and elastic modulus of the porcine aortic heart valve; in addition loss of extracellular matrix
components may affect the adhesion and proliferation of seeded cells on the valve [12-16].
What’s more, adequate mechanical stimuli, which can be provided by the dynamic bioreac-
tor in vitro, are conducive to improve the relevant mechanical properties of the valvular
complex, such as the mechanical strength and stiffness [17]. Therefore, to overcome these
limitations produced by decellularization, it is necessary to find a method or material with
good mechanical properties and good biological activity.
Covalent attachment of synthetic polymers to biological macromolecules offers an ef-
fective means to modify their properties, providing enhanced functionality for drug de-
livery and tissue engineering. One of the common approaches to achieve this goal is
the covalent attachment of poly (ethylene glycol) (PEG) to therapeutic proteins, termed
PEGylation. Therefore, the objective of the present study was to improve the mech-
anical properties of decellularized porcine aortic valve (DAV) and to promote its
endothelialization, which would further facilitate the development of TEHV. To achieve
this objective, we aimed to synthesize branched 4-arm poly (ethylene glycol) with the ter-
minal group of diacrylate (PEG-DA), DAV cross-linked by Michael addition reaction be-
tween acryloyl with thiol. We also aimed to covalently link the biological signaling
molecules (RGD peptide and VEGF) to the decellularized porcine aortic valve.
Materials and methods
Materials
PEG 20000, tert-octylphenylpolyoxyethylen (Triton-100), ethylenediaminetetraacetic
acid (EDTA), RNase A, DNase, and human recombinant VEGF165 were purchased
from Sigma. N-succinimidyl-S-acetylthioacetate (SATA) was purchased from Pierce
(Rockford, IL, USA). Gly-Arg-Gly-Asp-Ser-Pro-Cys (GRGDSPC) peptides and FITC-
Gly-Arg-Gly-Asp-Ser-Pro-Cys (FITC-GRGDSPC) peptides were obtained from GL
Biochem (Shanghai) Ltd. Water used in this study was distilled twice. This study was
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versity, China.
Synthesis and characterization of branched 4-arm-PEG-DA
The branched PEG-DA used in this study was synthesized by us. The schematic repre-
sentation of the synthesis is provided in Figure 1A. Briefly, linear PEG (MW= 20kDa)
was dissolved in dichloromethane, and allowed to react with methanesulfonyl chloride,
5-hydroxyl-mono-methyl isophthalate, lithium aluminium tetrahydride, and acryloyl
chloride, followed by purification procedures, to form branched PEG-DA. IR, 1H NMR
and 13C NMR were used to verify the final product.
PEGylation of decellularized valves
The schematic representation for the PEGylation of decellularized valves (i.e. construction
of PEG-DAV or PEG-crosslinking of decellularized valve) is presented in Figure 1B.
Porcine hearts were obtained from a local slaughterhouse. The porcine aortic valves
were excised from the hearts under sterile conditions; decellularization was performed
as described previously [18-20]. However, in this study, several modifications were ap-
plied. Briefly, after removal of adherent tissue the aortic valve leaflets were placed in a
solution of 0.05% Triton-100 with 0.02% EDTA in phosphate buffer solution (PBS) with-
out Ca2+ and Mg2+ for 24 hours under continuous shaking at 37°C, together with RNase A
(0.02 mg/mL) and DNase (0.2 mg/mL) followed by PBS supplemented with penicillin and
streptomycin flushing for 48 h with constant shaking to remove all cellular debris. The
valves were then stored in PBS at 4°C before further processing and seeding. To
characterize the decellularized scaffolds, routine histological examination by hematoxylin
and eosin (HE) and scanning electron microscopy (SEM) were performed [1,6,13,21].
SH-groups (Thiols) were introduced into the decellularized valve leaflets by a method
similar to the one previously described [22]. Briefly, forty decellularized valve leaflets
(mean dry weight 6.47 ± 1.34 mg per sample) were immersed in 50 mL of 50 mM PBS
(pH7.6, containing 1 mM EDTA) and allowed to react with 50 mg SATA for 2 h at
room temperature under continuous shaking. The reaction was then stopped by exten-
sive washing procedure with PBS. The acetylated sulfhydryl groups were deprotected
by adding 50 mL of 0.5 M hydroxylamine hydrochloride (NH2OH · HCl) in 50 mM PBS
(pH7.6) for 2 h at room temperature. Subsequently the leaflets were extensively washed
with PBS to remove the redundant hydroxylamine hydrochloride. To test the extent of
SH-modification, the leaflets which had been treated with SATA and hydroxylamine
hydrochloride were allowed to react with 10 mM DTNB (Ellman’s reagent, 5,5’-dithio-
bis-[2-nitrobenzoicacid], Sigma) in 100 mL disodium hydrogen phosphate solution
(50 mM, pH 8.0) for 15 min. After determination of the absorbance at 412 nm, the sulfhy-
dryl group contents of the decellularized valve leaflets was deduced from standard curves
obtained with cysteine [23]. Forty decellularized valve leaflets with introduced sulfhydryl
groups were immersed in 50 mL 0.1 M PBS (pH7.5, 5 mM EDTA), and allowed to react
with 500 mg branched 4-arm-PEG-DA for 8 h at 37°C under constant stirring. Finally,
Samples were rinsed with PBS to remove the excess PEG-DA. Morphological analysis of
PEGylated valves were performed using HE and SEM.
To evaluate the biomechanical properties of the PEGylated valves compared to native
and decellularized valves, the leaflets specimens were subjected to uniaxial planar, tensile
Figure 1 Schem tic representation of the branched 4-arm PEG-DA and different reactions. A: Schematic representation of the synthesis of branched 4-arm PEG-DA. B: Schematic
representation the PEGylation of decellularized valves. C: Schematic representation for the immobilization of decellularized valves by the GRGDSPC peptide. D: Schematic representation for the
immobilization decellularized valves by the VEGF165. E: Schematic representation for the simultaneous immobilization of decellularized valves by GRGDSPC peptide and VEGF165. F: The structure
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cumferential fiber direction. The tensile tests were performed on an Instron 5848
MicroTester (Instron Corporation, U.S.A.) at a constant speed of 5 mm/min until speci-
men fracture. Six specimens were tested in each group [6].
Preparation of GRGDSPC-PEG-DAV-PEG-VEGF165
The GRGDSPC peptide and Human recombinant VEGF165 was seperately immobilized co-
valently on decellularized valves by PEG-DA to find respective optimum reaction condi-
tions (Schematic representations are provided in Figure 1(C,D)). The PEG-crosslinked
decellularized valve was each reacted with 1 mL GRGDSPC peptide and Human recombin-
ant VEGF165 solution of different concentrations at 37°C. The amount of conjugation was
evaluated quantitatively by spectrophotometry and ELISA at different time points, and the
qualitative tests were performed by immunofluorescence (FITC-Ahx- Gly-Arg-Gly-Asp-
Ser-Pro-Cys, FITC-GRGDSPC,rabbit anti-human vascuoar endothelial cell growth factor
and goat anti-rabbit IgG/Cy3). The decellularized valves were used as a negative control.
Considering respective optimum reaction conditions, The PEG-crosslinked decellularized
valves were reacted with 1 mL reaction mixture solution (including 1 mg/mL GRGDSPC
peptide and 1000 pg/mLVEGF165) at 37°C for 4 h. Then the immunofluorescence was ana-
lyzed for qualitative evaluation of the conjugation effects. The decellularized valves were
used as a negative control (A schematic representation is provided in Figure 1E).
Biological function of signal molecules immobilized covalently on decellularized valves
After being cut into equal size disks (diameter = 1cm), DAVs, PEGylated decellularized
aortic valves (PEG-DAV) and RGD and VEGF-conjugated PEGylated decellularized
aortic valves (GRGDSPC-PEG-DAV-PEG-VEGF165) were put into different wells in a
24-well culture plate. HUVECs (KG110, Nanjing KeyGEN, China) [25] at 80% conflu-
ence were harvested using a 0.05% trypsin solution and condensed to a concentration
of 1 × 106/mL with serum-free media. A cell suspension of 0.5 mL was dropped on the
top of the scaffolds and incubated in humidified air with 5% CO2 at 37°C for 2 h to
allow adherence of the cells onto the scaffolds. Following this incubation, unattached
cells were removed with PBS, the cells/scaffolds constructs were then transferred into
another 24-well plate and cultured for the desired time period.
The DNA content of the scaffold seeded HUVECs was quantified with Hoechst Dye
33258 (Invitrogen, USA) at 4 and 8 days. The cells were harvested from six samples of each
group with 0.05% trypsin. Cells were centrifuged, lysed and then diluted lysates were incu-
bated with an equal volume of 0.1 mg/mL Hoechst 33258 Dye for 5 min in 96-well plates
protected from light. Fluorescence was determined with a FLUOstar Optima fluorescent
plate reader (BMG Labtech, Offenburg, Germany) at 352 nm excitation and 461 nm emis-
sion. The DNA content in each sample was determined according to a DNA standard
curve. SEM was performed for each group after 8 days of culture.
Statistical analysis
All quantitative data were expressed as mean ± standard deviations (mean ± SD). One-
way analysis of variance (ANOVA) was performed and confidence intervals (CI) were
determined using a statistical program (SPSS, Version 13.0, USA). p values of less than
0.05 were considered statistically significant.
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Identification of branched PEG-DA
The results of IR, 1H NMR and 13C NMR were as follows: IR (NaCl): 2883 cm-1, 1723 cm-1,
1467 cm-1, 1280 cm-1, 1112 cm-1, 946 cm-1, 842 cm-1; 1H NMR (CDCl3): 3.51-3.86
(OCH2CH2)n, 4.14 (4H, CH2OAr), 5.16 (8H, CH2-Ar), 5.88 (4H, CH=), 6.16 (4H, CH2=),
6.44 (4H, CH2=), 6.90-6.96 (6H, Ar);
13C NMR (CDCl3): 166.2, 159.3, 137.5, 131.2, 128.0,
113.9, 70.5. The structure of branched PEG-DA is given in Figure 1F.Characteristics of decellularization and assessment of sulfhydryl group introduction into
the decellularized valves
Decellularization procedures removed all cellular components of the valve leaflets,
whereas the extracellular matrix was well preserved and showed a loosened and porous
structure. The amount of sulfhydryl introduced into the decellularized valve (per mg
dry weight) was 0.815 ± 0.012 × 10-7mol by Ellman’s reagent.Scanning electron microscopy
Compared to decellularized valves, the surface of PEG-cross-linked decellularized valves
suggested they could form a thin film of PEG, the connections between the collagenous fi-
bers were significantly increased and fiber bundles were thickened (Figure 2).Mechanical testing of various valve leaflets
It was found that the decellularization procedure reduced the maximal tensile strength
of the acellular valves compared to the native valves (P < 0.05).There was no significant
difference with respect to the mechanical tensile strength properties between PEGylated
and native groups, n = 8 (Figure 3).Characteristics of GRGDSPC-PEG-DAV-PEG-VEGF165
The GRGDSPC peptides were conjugated effectively with the PEG-cross-linked
decellularized valves, shown by the FITC-GRGDSPC peptide giving high fluorescence in
the PEG-crosslinked decellularized valves. However, the negative controls showed little
fluorescence (Figure 4A). Moreover, the quantity of conjugated GRGDSPC peptidesFigure 2 Observations of decellularized valve and PEG-cross-linked decellularized valve under
scanning electron microscopy. SEM (×10000) of a decellularized valve (A) and a PEG-cross-linked
decellularized valve (B).
Figure 3 The maximal tensile strength as measured by using Instron 5848 MicroTester
(Instron Corporation, U.S.A.). Decellularized aortic valves (DAV, 5.65 ± 0.24) vs. native aortic valves
(NAV, 7.68 ± 0.19): p < 0.05; PEGylated decellularized aortic valves (PEG-DAV, 7.53 ± 0.25) vs. NAV: p > 0.05 n = 8.
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peptides in solution was 1 mg/mL and the reaction time was 2 h (Figure 4B).
The human recombinant VEGF165 were conjugated effectively with the PEG-cross
-linked decellularized valves, shown by the VEGF165 being highly positive in immuno-
fluorescence in the PEG-cross-linked decellularized valves, but the negative controls
showed little fluorescence (Figure 4C). Moreover, the quantity of conjugated VEGF165
reached a maximum of 896.87 ± 3.27 pg when the concentration of VEGF165 in solution
was 1000 pg/mL and the reaction time was 4 h (Figure 4D).
The GRGDSPC peptides and human recombinant VEGF165 were conjugated effectively
with the PEG-cross-linked decellularized valves simultaneously, since the GRGDSPC pep-
tide and VEGF165 were highly positive in immunofluorescence of the PEG-cross-linked
decellularized valves, but the negative controls showed little fluorescence (Figure 4E).Biological function of the GRGDSPC peptide and human recombinant VEGF165
immobilized covalently on decellularized valves: cellular immobilization and proliferation
The DNA content of the GRGDSPC-PEG-DAV-PEG-VEGF165 group at 4 and 8 days
were 26.91 ± 0.88 μg/scaffold and 30.59 ± 1.42 μg/scaffold, respectively, while those in
the DAV were 24.24 ± 0.68 μg/scaffold and 27.26 ± 1.35 μg/scaffold and in the PEG-
DAV group were 23.28 ± 1.25 μg/scaffold and 26.9 ± 1.17 μg/scaffold. The DNA content
of the DAV and PEG-DAV groups were significantly lower than those of the GRGDSPC-
PEG-DAV-PEG-VEGF165 group at 4 and 8 days (Figure 5A). Meanwhile, SEM revealed
that a confluent and compact monolayer was formed on the surface of the GRGDSPC-
PEG-DAV-PEG-VEGF165 group, but the other groups had clusters of scattered cells with
endothelial morphology (Figure 5B).Discussion
PEG is a hydrophilic polymer, which has a long flexible chain and is attractive to re-
searchers into the polypeptide/protein drugs and molecular-targeted therapies because of
its favorable biodegradability and biocompatibility [22,26,27]. Interestingly, functional
groups [28] (such as vinyl sulphone, acryloyl) can be introduced into the terminal hydroxyl
of PEG because of its strong controllability, which makes PEG widely used for chemical
Figure 4 The effect of conjugation under laser scanning confocal microscope and the amount of
conjugation. A: FITC-Ahx-GRGDSPC peptide conjugated on PEG-DAV under laser scanning confocal
microscope (×200) Scale bars, 50 μm,meanwhile,the negative control appears few fluorescence. B: The
quantity (mg) of GRGDSPC peptide in various concentrations immobilized on PEG-cross-linked decellularized
valves at a different time points(a) and its proportion in the original GRGDSPC peptide (%)(b) C: VEGF165
conjugated on PEG-DAV under laser scanning confocal microscope (×200)Scale bars, 50 μm, meanwhile, the
negative control appears few fluorescence D: The quantity (pg) of rh VEGF165 in various concentrations
immobilized on PEG-cross-linked decellularized valve at different points(α) and its proportion in the original
rh VEGF165 (%)(β) E: The express of GRGDSPC peptide (green) and VEGF165 (red) conjugated on DAV (4-6) and
PEG-DAV (1-3) (×200) 1 and 4 are the express of GRGDSPC peptide, 2 and 5 are the express of VEGF165, 3 and
6 are the simultaneous express of GRGDSPC peptide and VEGF165. Scale bars, 50 μm.
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of every branch of PEG, which provided a method for the covalently binding of thiols.
PEGylation is the covalent attachment of PEG to biomolecules of interest, such as
(poly) peptides and proteins. PEGylation was first reported by Abuchowski et.al in the
Figure 5 The quantification of DNA at different time among groups and scanning electron
photomicrographs of GRGDSPC-PEG-DAV-PEG-VEGF165 group. A: Quantification of DNA in the DAV,
PEG-DAV, GRGDSPC-PEG-DAV-PEG-VEGF165 groups at 4 and 8 days. Compared with DAV, *P > 0.05, **P < 0.05;
compared with PEG-DAV, ΔP < 0.01 B: Scanning electron photomicrographs depicting HUVECs adhesion and
proliferation on GRGDSPC-PEG-DAV-PEG-VEGF165 group after 8 days in culture (×2000).
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PEGylation has been broadened and developed tremendously [37,38]. An important as-
pect of PEGylation is the incorporation of various PEG functional groups that are used
to attach the PEG to the peptide or protein [39]. Collagen is one of the important com-
ponents of the extracellular matrix of heart valves; decellularization retains most of the
collagen component. Thus, PEGylation of decellularized valves is mainly PEGylation
of collagen.
Crosslinking of decellularized valves required dual functionality of PEG-DA. For the
first function, SH-groups were introduced into the collagen by SATA, then with excess
of acroloyl-groups on PEG-DA compared with the SH-groups on the decellularized
valves (the molar ratio of acroloyl-groups to SH-groups was 20:1), PEG-crosslinking of
decellularized valves was accomplished by the Michael addition reaction of the
acroloyl-groups and the SH-groups. In this study, the SEM showed that the surface of
the PEG-cross-linked decellularized valves formed a thin film of PEG, the connection
between collagenous fibers increased significantly and formed fiber bundles that were
thicker than with the decellularized valves. The biomechanical tests showed that the
tensile strength of the PEG-cross-linked decellularized valves had been notably en-
hanced compared with decellularized valves and there was no obvious difference with
native valves. The insertion of PEG molecules among the collagen molecules might
have cross-linked the collagen molecules to one another by the addition reaction of
acroloyl-groups and SH-groups, which in turn made the space structure of collagen in
the decellularized valves more stable.
The second function of PEG-DA allows the immobilization of biological signals, such
as RGD peptides and VEGF, immobilized covalently into decellularized valves is another
function of bifunctional PEG-DA. Using the Michael addition reaction of unsaturated
acroloyl-groups in PEG-cross-linked decellularized valves (i.e. unreacted acroloyl-groups in
PEG with SH-groups introduced into decellularized valves) with SH-groups in the
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decellularized valves. In this study, laser confocal microscopy observation and quantitative
detection (spectrophotometry and ELISA) showed that GRGDSPC peptide and VEGF can
not only be conjugated respectively, but can also be conjugated simultaneously by using
PEG-DA. More importantly, these biological signals can not only be conjugated into
decellularized valve, but also promote cell adhesion and cell proliferation, which was con-
firmed by the cellular DNA contents of each group and SEM.
Conclusions
Using the Michael addition reaction of acroloyl-groups in PEG-DA and SH-groups, not
only the PEG-cross-linking of decellularized valves can be accomplished, and biological sig-
nals can also be conjugated into decellularized valves, which can partially improve the par-
tial mechanical and biological properties of decellularized valves. Therefore, the novel
branched PEG-DA may be a potential cross-linking reagent for the modification of tissue
engineering scaffolds, which is expected to break through the traditional glutaraldehyde
cross-linking of bio-derived valve materials, and to overcoming the shortcomings of valve
decellularization. Further research and exploration of GRGDSPC-PEG-DAV-PEG-VEGF165
should be made into their wear over time and fluid dynamic performance, as well as the in-
teractions of signaling molecules cells and extracellular matrix in vivo or in a bioreactor.
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